ideasIdea
A same-week expert second opinion for every rare cancer diagnosis
Rare cancers are often misdiagnosed, which sends patients down the wrong treatment path. Digital slide sharing could get every case to an expert within days.
Reference pathology review changes the diagnosis in a substantial minority of sarcoma and rare tumour cases, and diagnosis determines treatment entirely. European reference networks and national sarcoma review panels show the model works, but coverage is incomplete and turnaround is slow. Whole-slide imaging plus a funded expert rota plus AI pre-screening for likely rare entities would make it universal.
Hypothesis
Mandatory digital reference review for suspected rare cancers changes diagnosis or management in at least 15% of cases and improves guideline-concordant treatment, with median turnaround under seven days.
Rationale
Centralised review already improves outcomes in sarcoma when patients are managed in reference centres. Digital pathology removes the physical slide logistics that limited previous schemes, and AI triage can flag which cases need expert eyes.
What would test it
A regional programme with mandatory digital review for a defined list of rare diagnoses, reporting diagnostic change rate, turnaround and downstream treatment concordance.
Maturity
being tested at scale
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Not enough oncologists, nurses, pathologists, physicists · The number of people with cancer is rising faster than the workforce trained to treat them.